Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
-
- STATUS
- Not Recruiting
-
- participants needed
- 57
-
- sponsor
- Novartis Pharmaceuticals
Updated on 3 April 2024
Summary
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients
with chronic stable schizophrenia.
Description
Details
| Condition | Schizophrenia Disorders |
|---|---|
| Age | 18years - 55years |
| Treatment | Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses) |
| Clinical Study Identifier | NCT01163227 |
| Sponsor | Novartis Pharmaceuticals |
| Last Modified on | 3 April 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.